3 active not recruiting, 3 recruiting, 2 unknown, 1 terminated. 5 Phase 2, 3 Phase 3, 1 Not applicable, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Active not recruiting 2, Unknown 2, Recruiting 1 |
| Phase 3 | 3 | Active not recruiting 2, Recruiting 1 |
| Not applicable | 1 | Terminated 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow this drug Literature Review of Taxoids trials Research Report on Taxoids
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis Biopsy Procedure, Biospecimen Collection, Breast Conservation Treatment - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 562 | 2027-03-09 | 2026-10-13 |
| The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC). Pyrotinib, Trastuzumab, Taxanes - HER2-positive Breast Cancer, Advanced Breast Cancer | Phase 4 | Recruiting | Hebei Medical University Fourth Hospital | 100 | 2024-01-02 | 2024-02-28 |
| Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC Pembrolizumab, CISPLATIN, Carboplatin - Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 28 | 2023-05-20 | 2026-06-23 |
| TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN) Trastuzumab, Taxanes, Pertuzumab - HER2-positive Breast Cancer, Brain Metastases | Phase 2 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 120 | 2021-10-01 | 2021-06-02 |
| Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer Pyrotinib, Epirubicin, Cyclophosphamide - Breast Cancer | Phase 2 / Phase 3 | Active not recruiting | Hebei Medical University Fourth Hospital | 113 | 2020-03-01 | 2026-01-07 |
| Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer Epirubicin plus Cyclophosphamide, Taxanes, Taxanes plus Carboplatin - Breast Neoplasm | Phase 3 | Active not recruiting | Shanghai Jiao Tong University School of Medicine | 786 | 2016-03-01 | 2025-07-11 |
| Prevention of Paclitaxel Neuropathy With Cryotherapy Cryotherapy, Paclitaxel - Breast Cancer | Phase 2 | Unknown | Medical Oncology & Hematology Associates of Northern Virginia | 39 | 2014-10-01 | 2015-10-01 |
| SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer AZD2014, AZD4547, AZD5363 - Metastatic Breast Cancer | Phase 2 | Active not recruiting | UNICANCER | 1460 | 2014-04-07 | 2025-01-15 |
| Evaluation of Chemotherapy Influence on Clinical and Biological Markers of Ovarian Reserve Biology and ultrasonography after chemotherapy - Infertility | Not applicable | Terminated | Assistance Publique - Hôpitaux de Paris | 19 | 2008-06-01 | 2013-05-14 |
Breast Neoplasms (4) · Brain Neoplasms (1) · Head and Neck Neoplasms (1) · Infertility (1) · Peripheral Nervous System Diseases (1) · Squamous Cell Carcinoma of Head and Neck (1)
Hebei Medical University Fourth Hospital (2) · Assistance Publique - Hôpitaux de Paris (1) · Dana-Farber Cancer Institute (1) · Medical Oncology & Hematology Associates of Northern Virginia (1) · SWOG Cancer Research Network (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Shanghai Jiao Tong University School of Medicine (1) · UNICANCER (1)
China (4) · United States (3) · France (2)
Kartik Sehgal, MD (1) · Kunwei Shen, professor (1) · Mariya Rozenblit (1) · Mary J Wilkinson, MD (1) · Renato Fanchin, MD (1) · Xuexin He, MD (1)
U10CA180888 (1)